Get the Stockscreener App
1.65
0.60%
-0.01
After Hours:
2.59
0.94
+56.97%
Dyadic International Inc., DE stock is currently priced at $1.65, with a 24-hour trading volume of 33,615.
It has seen a -0.60% decreased in the last 24 hours and a -1.79% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $1.64 pivot point. If it approaches the $1.74 resistance level, significant changes may occur.
Previous Close:
$1.66
Open:
$1.7
24h Volume:
33,615
Market Cap:
$48.24M
Revenue:
$2.96M
Net Income/Loss:
$-6.87M
P/E Ratio:
-7.1739
EPS:
-0.23
Net Cash Flow:
$-7.49M
1W Performance:
+13.80%
1M Performance:
-1.79%
6M Performance:
-3.51%
1Y Performance:
-21.43%
1D Range:
$1.65
$1.75
52W Range:
$1.19
$2.40
Dyadic International Inc., DE Stock (DYAI) Company Profile
Name
Dyadic International Inc., DE
Sector
Industry
Phone
561 743 8333
Address
140 Intracoastal Pointe Drive, Suite 404, Jupiter
Dyadic International Inc., DE Stock (DYAI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-18-22 | Downgrade | Dawson James | Buy → Neutral |
| Dec-17-21 | Initiated | H.C. Wainwright | Buy |
Dyadic International Inc., DE Stock (DYAI) Latest News
Fermbox Bio launches its first product in its Synbio product pipeline: A cellulosic enzyme cocktail to transform ... - Big News Network
Big News Network
Dyadic Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress - GlobeNewswire
GlobeNewswire
Dyadic to Attend Industry and Investor Events in May
GlobeNewswire Inc.
Dyadic to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024
GlobeNewswire Inc.
Biocatalysis and Biocatalyst: A Market with Huge Potential and Growth Opportunities – Market Research Blog - Market Research Blog
Market Research Blog
Dyadic Reports 2023 Full Year Results and Recent Company Progress
GlobeNewswire Inc.
Dyadic International Inc., DE Stock (DYAI) Financials Data
Dyadic International Inc., DE (DYAI) Revenue 2024
DYAI reported a revenue (TTM) of $2.96 million for the quarter ending September 30, 2023, a +18.24% rise year-over-year.
Dyadic International Inc., DE (DYAI) Net Income 2024
DYAI net income (TTM) was -$6.87 million for the quarter ending September 30, 2023, a +41.79% increase year-over-year.
Dyadic International Inc., DE (DYAI) Cash Flow 2024
DYAI recorded a free cash flow (TTM) of -$7.49 million for the quarter ending September 30, 2023, a +17.17% increase year-over-year.
Dyadic International Inc., DE (DYAI) Earnings per Share 2024
DYAI earnings per share (TTM) was -$0.23 for the quarter ending September 30, 2023, a +45.24% growth year-over-year.
About Dyadic International Inc., DE
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and collaboration with Syngene International Limited. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
0.77%
1.20%
Cap:
|
Volume (24h):